Torsemide Can Cause Hypocalcemia Through Enhanced Urinary Calcium Excretion
Torsemide, like other loop diuretics, increases urinary calcium excretion and can lower serum calcium levels, though this effect is generally less pronounced than with furosemide. 1
Mechanism of Calcium Loss
Loop diuretics act on the thick ascending limb of the loop of Henle, where they inhibit the sodium-potassium-chloride cotransporter. This action disrupts the positive luminal charge that normally drives paracellular calcium reabsorption, resulting in increased urinary calcium losses 2.
Clinical Evidence on Calcium Effects
Comparative Calciuretic Effects
Research demonstrates that torsemide promotes calcium excretion to a lesser extent than furosemide 2, 3. In patients with chronic renal failure receiving 20 mg IV torsemide, calcium excretion showed tight correlation with sodium excretion over a broad range of creatinine clearances 3. However, one study in advanced renal failure patients receiving high-dose torsemide (200 mg IV daily for 7 days) found only minor changes in calcium excretion after repeated dosing, with no alteration in phosphate excretion 4.
Dose-Response Relationship
In healthy volunteers, urinary calcium excretion increased linearly with the logarithm of torsemide dose (5-20 mg), alongside sodium and chloride excretion 5. Genetic factors also influence calcium response—subjects with two deletion alleles of the ACE insertion/deletion polymorphism excreted 32 mg more calcium, while those with two GNB3 T-alleles excreted 42 mg less 6.
Monitoring Requirements
The FDA label explicitly warns that torsemide can cause potentially symptomatic hypocalcemia 1. Current heart failure guidelines recommend:
- Check electrolytes (including calcium) 1-2 weeks after each dose increment 7
- Monitor at 3 months, then at 6-month intervals during maintenance therapy 7
- Daily electrolyte monitoring during hospitalization 8
Clinical Implications
Risk Stratification
Patients at highest risk for clinically significant hypocalcemia include those with:
- Chronic kidney disease (particularly eGFR <30 mL/min)
- Malabsorption disorders
- Concurrent use of medications that lower calcium (e.g., denosumab, which requires calcium monitoring within 14 days of injection) 9
- Pre-existing hypoparathyroidism or vitamin D deficiency
Practical Management
While torsemide's calciuretic effect is real, it rarely causes symptomatic hypocalcemia in patients with normal parathyroid function and adequate vitamin D stores. The more clinically relevant electrolyte disturbances are hypokalemia, hyponatremia, and hypomagnesemia 1.
For patients requiring chronic loop diuretic therapy, ensure adequate calcium and vitamin D intake, particularly if they have risk factors for hypocalcemia. In patients with hypoparathyroidism on conventional therapy (calcium and calcitriol), loop diuretics can exacerbate hypercalciuria and increase risk of nephrocalcinosis—maintain serum calcium in the lower half of normal range to minimize this risk 10.
The duration of torsemide's action (12-16 hours) 11 means calcium losses occur over a more prolonged period compared to furosemide (6-8 hours), but the total calcium loss per dose appears lower due to torsemide's relatively calcium-sparing properties 2.